- Trials with a EudraCT protocol (16)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
16 result(s) found for: economic growth.
Displaying page 1 of 1.
EudraCT Number: 2016-000968-42 | Sponsor Protocol Number: PRPZDSKIN | Start Date*: 2016-06-23 |
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE | ||
Full Title: Study on the healing of the partial skin graft donor site in burn patients after application of platelet-rich plasma (PRP) or plasma rich in growth factors versus usual therapeutical practice. | ||
Medical condition: Study on healing the graft donor skin on burn patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005117-72 | Sponsor Protocol Number: AG120-C-005 | Start Date*: 2017-04-24 | ||||||||||||||||
Sponsor Name:Agios Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation | ||||||||||||||||||
Medical condition: Nonresectable or Metastatic Cholangiocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004035-24 | Sponsor Protocol Number: I3Y-MC-JPCW | Start Date*: 2021-04-26 | ||||||||||||||||
Sponsor Name:Eli Lilly and Company | ||||||||||||||||||
Full Title: eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER2+ Early Brea... | ||||||||||||||||||
Medical condition: High-Risk, Node-Positive, HR+, HER2+ Breast Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) BE (Completed) DE (Completed) FI (Prematurely Ended) AT (Completed) HU (Completed) GR (Completed) IT (Completed) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001998-10 | Sponsor Protocol Number: Create-01 | Start Date*: 2011-10-17 | |||||||||||
Sponsor Name:Department of Oncology University Hospital Uppsala | |||||||||||||
Full Title: An International Randomized Phase II Study Comparing Early Electrochemotherapy to Delayed or No Electrochemotherapy in Patients with Cutaneous Breast Cancer Metastases | |||||||||||||
Medical condition: Breast cancer that has spread to the skin | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005589-37 | Sponsor Protocol Number: RMRHS0095 | Start Date*: 2013-03-08 | ||||||||||||||||
Sponsor Name:University of Warwick | ||||||||||||||||||
Full Title: select-d: Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism | ||||||||||||||||||
Medical condition: Venous Thromboembolism and Cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-004241-17 | Sponsor Protocol Number: TEST_PILOT_V1 | Start Date*: 2014-01-06 |
Sponsor Name:University College Dublin CRC | ||
Full Title: An Open-Label Randomized-Controlled Trial of Early Screening Test For Pre-Eclampsia and Growth restriction : A Pilot Study (TEST Study) | ||
Medical condition: Pre-eclampsia (PET) is a serious systemic condition, which affects 3-5% of all pregnancies and accounts for more than 50,000 of maternal deaths annually. Administration of anti-platelet agents to ... | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-003556-31 | Sponsor Protocol Number: SHP-607-201 | Start Date*: 2015-02-10 |
Sponsor Name:Premacure AB, A Member of the Shire Group of Companies | ||
Full Title: Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated with rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care | ||
Medical condition: Retinopathy of Prematurity (ROP) | ||
Disease: | ||
Population Age: Newborns, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002190-66 | Sponsor Protocol Number: HS-19-647 | Start Date*: 2019-07-12 | |||||||||||
Sponsor Name:Camurus AB | |||||||||||||
Full Title: A Phase 3, open-label, single-arm, multi-center trial to assess the long term safety of octreotide subcutaneous depot (CAM2029) in patients with acromegaly | |||||||||||||
Medical condition: Acromegaly | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) ES (Ongoing) GR (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001486-27 | Sponsor Protocol Number: 1301-LG | Start Date*: 2015-05-29 | |||||||||||||||||||||||||||||||
Sponsor Name:European Orgainzation for the Research and Treatment of Cancer (EORTC) | |||||||||||||||||||||||||||||||||
Full Title: 10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS... | |||||||||||||||||||||||||||||||||
Medical condition: Acute Myeloid Leukaemia (AML) in elderly population (equal or older than 60 years). | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: BE (Completed) DE (Completed) PT (Completed) LT (Completed) SK (Completed) BG (Completed) NL (Completed) IT (Completed) FR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-006063-28 | Sponsor Protocol Number: SHR3162-III-305 | Start Date*: 2021-10-07 | |||||||||||||||||||||
Sponsor Name:Jiangsu Hengrui Medicine Co., Ltd | |||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Placebo Combined with AA-P as First-Line Tr... | |||||||||||||||||||||||
Medical condition: Metastatic Castration-Resistant Prostate Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002157-38 | Sponsor Protocol Number: 57911 | Start Date*: 2017-09-14 | ||||||||||||||||||||||||||
Sponsor Name:Radboud University Medical Center | ||||||||||||||||||||||||||||
Full Title: Treatment of congenital vascular malformations using Sirolimus: improving quality of Life | ||||||||||||||||||||||||||||
Medical condition: congenital vascular malformation : Vascular malformations can involve lymphatic vessels, capillaries, veins and arteries or even combinations. These vascular malformations are present at birth an... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-023198-21 | Sponsor Protocol Number: STH15295 | Start Date*: 2011-05-25 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: The Relative Effectiveness of Pumps Over MDI and Structured Education. | |||||||||||||
Medical condition: Type-1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004511-36 | Sponsor Protocol Number: HM13/10993 | Start Date*: 2015-09-28 | |||||||||||
Sponsor Name:University Of Leeds | |||||||||||||
Full Title: A randomised phase II trial of Cyclophosphamide and Dexamethasone in combination with Ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with tha... | |||||||||||||
Medical condition: Relasped and Refractory Mulitple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021994-35 | Sponsor Protocol Number: A4001098 | Start Date*: 2011-06-30 | |||||||||||
Sponsor Name:ViiV Healthcare UK Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Blinded, Placebo Controlled Study To Evaluate The Safety Of Maraviroc In Combination With Other Antiretroviral Agents In HIV-1 Infected Subjects Coinfected With Hepatitis... | |||||||||||||
Medical condition: HIV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) DE (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000222-61 | Sponsor Protocol Number: DS8201-A-U302 | Start Date*: 2019-02-06 | |||||||||||
Sponsor Name:Daiichi Sankyo Inc. | |||||||||||||
Full Title: A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate, versus ado-trastuzumab emtansine (T-DM1) for HER2... | |||||||||||||
Medical condition: Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) DE (Completed) IT (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002148-56 | Sponsor Protocol Number: ACT-CS-005 | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:ACTICOR BIOTECH | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE BLIND, MULTICENTER, MULTINATIONAL, PLACEBO CONTROLLED, PARALLEL GROUP, SINGLE DOSE, ADAPTIVE EFFICACY AND SAFETY STUDY OF GLENZOCIMAB USED AS AN ADD-ON THERAPY ON TOP OF STANDA... | |||||||||||||
Medical condition: Acute ischemic stroke | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) SK (Completed) ES (Ongoing) CZ (Completed) DK (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
